EUVIMEDEUVIMED entdecken
Crossref

A CRISPR-Cas12a Fluorescent Aptasensor for Point-of-Care Drug Concentration Detection: A Synergistic Regulation by DNA Aptamer and RNA Blocker

Chen Huang, Ling-Jie Guo, Jia-Yi Li, Yue-Wen Chen, Bing Wu, Yi-Wei Liu, Chen-Zhi Zhang, Wei-Wei Lin, Ye Yang, Jin-Yuan Chen iD, Zhou-Jie Liu iD

Analytical Chemistry · 2025

DOI: 10.1021/acs.analchem.5c03744 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytical Chemistry, 2025. Verfasst von Chen Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350212, C…. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, CRISPR-Cas Systems, Biosensing Techniques, Point-of-Care Systems. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Natural Science Foundation of Fujian Province, National Natural Science Foundation of China, Joint Funds for the Innovation of Science and Technology, Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination of CRISPR-Cas12a with aptamers can potentially improve the sensitivity, specificity, and speed of non-nucleic acid target detection. Nevertheless, current CRISPR-Cas12a aptasensors, solely dependent on aptamer affinity and overlooking the enzymatic regulation of CRISPR-Cas12a, may produce false-positive signals. We proposed a CRISPR-Cas12a aptasensor synergistically regulated by an aptamer and RNA, which incorporated aptamer-mediated drug recognition and CRISPR-powered signal amplification in a one-pot format. Herein, a regulatory RNA probe synergized with the conformational switching of a drug-induced aptamer, enabling precise regulation of Cas12a trans-cleavage activity via toehold-mediated strand displacement (TMSD). This dual regulatory mechanism transformed the aptamer-activated CRISPR-Cas12a sensing process into a TMSD-driven conditional reaction, avoiding false-positive signals and thus achieving better detection performance with a lower detection limit. With the vancomycin (VCM) aptamer as a model, the aptasensor can detect VCM within 30 min from 2% serum, 1% synovial fluid, and 1% cerebrospinal fluid, with a detection limit of 13.62, 7.56, and 6.75 nM, respectively. The proposed aptasensor was incorporated into a custom 3D-printed portable fluorometer and underwent clinical validation in 22 VCM serum samples, reporting no significant difference when compared with the enzyme-multiplied immunoassay technique, confirming the reliability for point-of-care quantification. It further received cross-validation with a quinine aptamer, suggesting universality [a linear range of 10-250 nM (R2 = 0.985) and a detection limit of 0.42 nM]. By integration of aptamer selectivity with CRISPR programmability, this work presents a novel robust biosensing paradigm for point-of-care drug concentration detection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aptamers, NucleotideCRISPR-Cas SystemsBiosensing TechniquesPoint-of-Care SystemsVancomycinRNAFluorescent DyesAnti-Bacterial AgentsLimit of DetectionHumansBacterial ProteinsEndodeoxyribonucleasesCRISPR-Associated Proteins

Substanzen

Aptamers, NucleotideVancomycinRNAFluorescent DyesCas12a proteinAnti-Bacterial AgentsBacterial ProteinsEndodeoxyribonucleasesCRISPR-Associated Proteins

Autor:innen und Institutionen

  • Department of Pharmacy, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350212, China.
  • The First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, China.

ORCID-Profile: Jin-Yuan Chen, Zhou-Jie Liu

Förderung

  • Natural Science Foundation of Fujian Province
  • National Natural Science Foundation of China
  • Joint Funds for the Innovation of Science and Technology, Fujian Province

Zitieren

APA

Huang, C., Guo, L. J., Li, J. Y., Chen, Y. W., Wu, B., Liu, Y. W., Zhang, C. Z., Lin, W. W., Yang, Y., Chen, J. Y., & Liu, Z. J. (2025). A CRISPR-Cas12a Fluorescent Aptasensor for Point-of-Care Drug Concentration Detection: A Synergistic Regulation by DNA Aptamer and RNA Blocker. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.5c03744

Vancouver

Huang C, Guo LJ, Li JY, Chen YW, Wu B, Liu YW, et al. A CRISPR-Cas12a Fluorescent Aptasensor for Point-of-Care Drug Concentration Detection: A Synergistic Regulation by DNA Aptamer and RNA Blocker. Analytical Chemistry. 2025. doi:10.1021/acs.analchem.5c03744

BibTeX
@article{Huang2025,
  author = {Huang, Chen and Guo, Ling-Jie and Li, Jia-Yi and Chen, Yue-Wen and Wu, Bing and Liu, Yi-Wei and Zhang, Chen-Zhi and Lin, Wei-Wei and Yang, Ye and Chen, Jin-Yuan and Liu, Zhou-Jie},
  title = {A CRISPR-Cas12a Fluorescent Aptasensor for Point-of-Care Drug Concentration Detection: A Synergistic Regulation by DNA Aptamer and RNA Blocker},
  journal = {Analytical Chemistry},
  year = {2025},
  doi = {10.1021/acs.analchem.5c03744}
}
Kostenlos starten →